Pain is an important clinical manifestation in multiple sclerosis (MS) patients, though it has been neglected in clinical and experimental researches. Objective: To investigate the nociceptive response in MOG 35-55 experimental autoimmune encephalomyelitis (EAE)-induced mice. Method: EAE was induced in 8 to 10 week old C57BL/6 female mice with an emulsion of MOG , Complete Freund Adjuvant, Mycobacterium tuberculosis H37 RA and pertussis toxin. Nociception was evaluated by the von Frey filaments method. A clinical scale ranging from 0 to 15 was used to assess motor impairment. Results: Clinical evidence of disease started at day 10 and peaked at day 14 after immunization. Thereafter, there was no worsening of symptoms until day 26. The EAE-induced mice presented reduced pressure threshold at days 7 th and 10 th after immunization and before the onset of clinical motor signs. Conclusion: The hypernociception found validates MOG 35-55 EAE as a model for the study of pain in multiple sclerosis.
Multiple sclerosis (MS) is considered an autoimmune inflammatory disease affecting 2.5 million people worldwide. Its defining feature is the central nervous system (CNS) demyelinating lesions in association with inflammatory infiltrates. Axonal injury can also occur 1 . Clinical signs of MS include sensory disturbances, optic neuritis, diplopia, Lhermitte's sign, limb weakness, clumsiness, gait ataxia, neurogenic bladder, bowel symptoms and also pain 2 . Although many MS patients describe pain as their worst symptom 3 , only recently pain has been systematically studied in MS patients 4, 5 . Pain in MS can be ascribed to a variety of conditions such as musculoskeletal pain, painful spasms, trigeminal neuralgia, and central pain due to sclerotic plaque lesions affecting sensorial pathways in the CNS 4 . In the search of a better understanding of MS, investigators have been using many experimental models, including the experimental autoimmune encephalomyelitis (EAE). EAE can be induced in susceptible species by many different protocols usually with an emulsion containing one of these three molecules: MBP (myelin basic protein), PLP (proteolipid protein) or MOG (myelin oligodendrocyte glycoprotein) 6 . In spite of the relevance of pain in MS, there are only a few studies investigating pain in EAE, none related to MOG 35-55 -induced EAE.
Hence, in the present study, we intended to investigate whether MOG 35-55 EAE-induced mice had altered mechanical nociception.
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Animals
Animal care and handling procedures were in accordance with the guidelines of the International Association for Study of Pain and had prior approval from the local animal ethics committee (Comitê de Ética em Experimentação Animal, CETEA/UF-MG, Certificate number 007/2007). Eight to 10 weeks old female C57Bl/6J (WT) mice were obtained from Centro de Bioterismo (CEBIO) of the Universidade Federal de Minas Gerais (UFMG, Brazil) and maintained in the animal facilities of the Laboratory of Immunopharmacology, Department of Biochemistry and Immunology (UFMG, Brazil), with filtered water, food ad libitum and in a controlled environment (temperature and humidity). Animals were divided in two groups: MOG 35-55 EAE induced mice (n=8) and control mice injected with saline (n=8).
EAE induction
EAE was induced by s.c. immunization (base of tail) with an emulsion containing 100 mg MOG 35-55 peptide (MEVGWYRSPFS-RVVHLYRNGK; NeoMPS) and CFA supplemented with 4 mg/mL Mycobacterium tuberculosis H37 RA (Difco Laboratories). Pertussis toxin, 300 ng/animal was injected i.p. on the day of immunization and again 48h later 7 .
Daily assessments of disease in mice Animals were evaluated daily using a previously described scale 8 . This scale ranges from 0 to 15 and is the sum of the state of the tail and all of the four limbs. For the tail, a score of 0 reflects no sign, 1 represents a partial paralyzed tail, while a score of 2 is given to a mouse with a fully paralyzed tail. For each of the hind-or forelimbs, each assessed separately, 0 signifies no sign, a score of 1 is an altered gait, 2 represents paresis, while a score of 3 denotes a fully paralyzed limb. Thus, a fully paralyzed quadriplegic animal would attain a score of 14. Mortality equals a score of 15. Typically, a mouse undergoing an attack would first have loss of function in the tail followed by one of the hindlimbs. Therefore, a low score of 3 or 4 indicates tail involvement and a weak hindlimb, akin to Grade 2 on the commonly used 5 point scale 9 . Animals were also weighed daily.
Nociceptive mechanical test
The term ''hypernociception'' was used to define the decrease of nociceptive withdrawal threshold 10 .
Mechanical hypernociception was tested in mice as reported previously 11, 12 . Briefly, in a quiet room, mice were placed in 12 × 10 × 17-cm acrylic cages with wire grid floors 15-30 min before the start of testing. The test consisted of evoking a hindpaw flexion reflex with a hand-held force transducer (Electronic Anesthesiometer, Insight mod. EFF-301, Brazil) adapted with a 0.5-mm 2 polypropylene tip. The investigator was trained to apply the tip perpendicularly to the central area of the hindpaw with a gradual increase in pressure. The endpoint was characterized by the removal of the paw, followed by clear flinching movements. After the paw withdrawal, the intensity of the pressure was automatically recorded. The value for the response was obtained by averaging three measurements. Animals were tested before and after treatments. Results are expressed as Δ withdrawal threshold (in g) calculated by subtracting zero-time mean measurements from the time interval mean measurements.
Statistical analysis
Results are shown as the mean ±SD. Difference among groups was evaluated by using analysis of variance (ANOVA) followed by Student-Newman-Keuls post-hoc test. The level of significance was set a p<0.05.
results
Kinetics of clinical changes in EAE mice
The severity of MOG 35-55 -induced EAE was assessed daily using a previously validated scale 8 . Clinical evidence of disease was first noticed at day 10 and peaked at day 14 after immunization. Thereafter, there was no worsening of symptoms till day 26 ( Fig 1A) . Tail paralysis and hind limb weakness was the major clinical feature noticed. Paralleling the clinical symptoms above, there was significant weight loss which peaked at day 14 after disease induction when compared with control mice (Fig 1B) .
Fig 1. Experimental autoimmune encephalomyelitis (EAE) clinical signs (A) and body weights loss (B) were monitored in control and EAE-induced mice. This kinetics study includes the time points 1 to 26 day post-induction of EAE with MOG35-55. Data is according to maximal clinical score achieved at any time during experimental design. The data are the means (±SD) of eight animals per group.
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MOG 35-55 -induced mechanical hypernociception
The immunization of mice with MOG 35-55 peptide brought about a mechanical hypernociception. The intensity of hypernociception was assessed daily in EAE and control mice. The mechanical hypernociception was observed in EAE mice on the 7 th and 10 th days after immunization (Fig 2) . The intensity of hypernociception was assessed before clinical evidence of disease that was first noticed at day 10. We did not evaluate mechanical nociception after 10 days, as the results could be affected by the motor condition of the animals.
Discussion
To the best of our knowledge, this is the first study of nociception in MOG 35-55 -induced EAE in C57BL/6 mice. We found hypernociception in EAE mice before the onset of motor disability.
Hypernociception was also found in a recent study 13 which observed thermal hyperalgesia and mechanical allodynia during disease progression in the Theiler's virus experimental model of MS (Theiler's murine encephalomyelitis virus, TMEV). The TMEV model displays a clinical outcome similar to MS, but the autoimmune response observed in MS is not described for this experimental model. By contrast, EAE presents many pathophysiological similarities to MS and is considered a more suitable model for this CNS disease 14 .
A previous study 15 found hyponociception and hypernociception during acute and chronic phases, respectively, using a heat stimulus method. In that study, the investigators used a PLP-induced EAE model and evaluated nociception after the onset of clinical disability, which could have interfered with results. The hypernociception found in the chronic phase of EAE may suggest that the PLPinduced model is a good model to evaluate chronic pain, which is also found in MS 16 . However, that model was unable to detect acute pain, a common problem for many MS patients 17, 18 . We described hypernociception before the onset of clinical impairment using the MOG 35-55 EAE model. Therefore this could be a better model to study acute pain in MS. As the animals had severe motor impairment after onset of clinical signs, we avoided the measurement of nociception after 10 days of EAE induction.
A study using an EAE model of Lewis rats found hyponociception during acute phase of disease using a vocalization method of response to noxious mechanical stimulation of the tail 19 . They concluded that hyponociception was due to demyelination of small diameter fibres in the sacrococcygeal dorsal root ganglia, dorsal roots and dorsal root entry zones. However, in our EAE model, demyelination is not so evident, especially before the onset of clinical signs 20 . Hence, the hypernociception observed in our results may be caused by other pathways.
Immune response before onset of clinical signs in this experimental model of MS is evidenced by several studies. Increased rolling of leukocytes 7 and increase of CD4 + T cells in draining lymph nodes 21 after 7 days postimmunization; increase of P-selectin in CNS after 8 days post-immunization 22 and increase in IFN-γ after 10 days post-immunization 23 are some of the immune events that happen before motor disability of the animals. Thus, the hypernociception observed in our study may be the result of the intrinsic immune response from the 7 th to the 10 th day after immunization. Cytokines were found to mediate hypernociception in a carrageenan-induced inflammatory model of hyperalgesia 10 and chemokines (chemotactic cytokines) seem to be involved in the hypernociception elicited by an experimental model of arthritis 24 . Chemokines are also important in MS 25, 26 and they are involved in many pathways of pain 27 . The possibility of chemokines being the cause of pain in MS was discussed elsewhere 28 . Nonetheless, further studies are needed to investigate whether cytokines or other immune factors are involved in the hypernociception of MOG 35-55 EAE mice.
In conclusion, the hypernociception observed indicates that the MOG 35-55 EAE model may be a useful tool to study the mechanisms of pain in MS.
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